|
Synonyms: Aerumab 11 | Aerumab™ | AR-101 | KBPA101
Compound class:
Antibody
Comment: Panobacumab is a fully human IgM kappa monoclonal antibody directed against the O-polysaccharide component of surface lipopolysaccharide (LPS) of serotype O11 Pseudomonas aeruginosa [1]. It is under clinical development as an adjunctive immunotherapy for the treatment of nosocomial pneumonia caused by O11 serotype P. aeruginosa.
Annotated peptide sequences for this monoclonal antibody are available from its IMGT/mAb-DB record. |
| References |
|
1. Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, Hoiby N, Fas SC, Lang AB. (2010)
Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother, 54 (6): 2338-44. [PMID:20308370] |
|
2. Lu Q, Rouby JJ, Laterre PF, Eggimann P, Dugard A, Giamarellos-Bourboulis EJ, Mercier E, Garbino J, Luyt CE, Chastre J et al.. (2011)
Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother, 66 (5): 1110-6. [PMID:21398296] |
|
3. Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E et al.. (2014)
Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis, 33 (10): 1861-7. [PMID:24859907] |
